IF
Ian Feiner
Founder & Compound Researcher, Meridian Compounds
Ian Feiner is the founder of Meridian Compounds and an independent biohacker and compound researcher. He writes Meridian's research library to summarize the published literature on research compounds in plain language — always framed for laboratory and research use only.
Editorial standards
Every article in the Meridian research library is written to a single standard: it summarizes what the published literature has explored, in plain language, and it cites its sources. Nothing is presented as medical advice, and every compound is described strictly for laboratory and research use — never with claims of human benefit, dosing, or treatment. Where the evidence is preclinical (as it is for most research compounds), we say so plainly.
Articles by Ian
BPC-157: A Plain-Language Overview of the ResearchJul 2026How to Read a Compound Certificate of Analysis (CoA)Jun 2026Tesamorelin: A Research Literature OverviewJun 2026MOTS-c: An Overview of the Mitochondrial-Compound ResearchJun 2026NAD+ in Research: A Plain-Language OverviewMay 2026Semax: What the Nootropic Compound Research ExploresMay 2026Selank: A Plain-Language Research OverviewMay 2026Retatrutide: The Triple-Agonist Research StoryApr 2026Tirzepatide: A GIP/GLP-1 Research OverviewApr 2026Semaglutide and the GLP-1 Research LandscapeApr 2026CJC-1295 (No DAC): A Research OverviewMar 2026Ipamorelin: An Overview of the Research LiteratureMar 2026GHK-Cu: What the Copper-Compound Research ExploresFeb 2026TB-500: A Plain-Language Overview of the ResearchFeb 2026